1. SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY). (17th June 2021) Authors: Trotman, J.; Tedeschi, A.; Linton, K.; McKay, P.; Hu, B.; Chan, H.; Jin, J.; Sobieraj‐Teague, M.; Zinzani, P. L.; Coleman, M.; Browett, P.; Ke, X.; Sun, M.; Marcus, R.; Portell, C.; Thieblemont, C.; Zhou, K.; Liberati, A. M.; Bachy, E.; Cavallo, F. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting2. Issue 4 (11th April 2013) Authors: Berger, J.; Eikelboom, J. W.; Quinlan, D. J.; Guyatt, G.; Büller, H. R.; Sobieraj‐Teague, M.; Harrington, R. A.; Hirsh, J. Journal: Journal of thrombosis and haemostasis Issue: Volume 11:Issue 4(2013) Page Start: 778 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗